Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia

Launched by UNIVERSITAT INTERNACIONAL DE CATALUNYA · Mar 18, 2015

Keywords

ClinConnect Summary

Androgenetic alopecia (AGA) is a non-scarring patterned alopecia, multifactorial and a genetic determined skin condition. This pathology is one of the most common forms of progressive hair loss. It's an increasingly frequent complaint of dermatology clinic patients and has a high impact psychologically.

The onset of AGA is gradual and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. As a result, more hairs are in the telogen phase, and the patient may notice an increase in hair shedding. This area varies from patient to patient and is usuall...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients ≥18 years and \< 65 years
• • Male patients with a clinical diagnosis of AGA (stage II to V according to the Hamilton-Norwood Scale)
• • Female patients with a clinical diagnosis of AGA (stage I to III according to Ludwig Classification)
• Exclusion Criteria:
• • Patients with other types of alopecia, other than AGA
• • Fasting \< 3h prior of each injection
• • Use of nonsteroidal anti-inflammatory drugs one week before treatment.
• • Platelet count \< 150 000 μL
• • Alterations of coagulation
• • Heavy smokers (\> 20 cigarettes/day)
• • Medications: anticoagulants/ acetylsalicylic acid
• • Patient unable to accomplishing all fases of treatment